Subsequently, we defined a higher confidence patient population by differentiating between candidate genes in which the primary role is related to mismatch repair or where, despite a purported role in double-strand DNA repair, either the genetic mechanism is distinct and/or the phenotypic impact on platinum sensitivity and prognosis in ovarian cancer is directionally opposed to that of BRCA mutations (i.e., EMSY amplification and PTEN loss).8 Here, PTEN is linked to ovarian cancer.